Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.

Conclusions: Utilization of neoadjuvant SBRT for pancreatic cancer is increasing. In the neoadjuvant setting, chemo-SBRT may improve R0 resection and OS over chemotherapy and chemo-CFRT, although confirmatory prospective studies are needed for confirmation. PMID: 31237185 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31237185?dopt=Abstract

Source: Acta Oncologica - June 24, 2019 Category: Cancer & Oncology Authors: Jiang W, Haque W, Verma V, Butler EB, Teh BS Tags: Acta Oncol Source Type: research